R. Albazaz

Dr. R. Albazaz


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2023 in British Journal of Radiology
Verified
Journal Article
Open access
ZRZena C Riddell
Zena C Riddell
CCCarmelo Corallo
Carmelo Corallo
RAR. Albazaz
R. Albazaz
KFKieran G Foley
Kieran G Foley
Incidental findings are commonly detected during examination of the gallbladder. Differentiating benign from malignant lesions is critical because of the poor prognosis associated with gallbladder malignancy. Therefore, it is important that radiologists and sonographers are aware of common incidental gallbladder findings, which undoubtedly will continue to increase with growing medical imaging use. Ultrasound is the primary imaging modality used to examine the gallbladder and biliary tree, but contrast-enhanced ultrasound and MRI are increasingly used. This review article focuses on two common incidental findings in the gallbladder; adenomyomatosis and gallbladder polyps. The imaging features of these conditions will be reviewed and compared between radiological modalities, and the pathology, epidemiology, natural history, and management will be discussed.

1 November 2020 in Clinical Radiology
Verified
Journal Article
Closed access
JZJ. Zhong
J. Zhong
CSC. Smith
C. Smith
PWP. Walker
P. Walker
MSM. Sheridan
M. Sheridan
AGA. Guthrie
A. Guthrie
RAR. Albazaz
R. Albazaz

24 October 2024 in British Journal of Radiology
Verified
Journal Article
Open access
PDF file
CCCarmelo Corallo
Carmelo Corallo
AAAbdullah Saad Al-Adhami
Abdullah Saad Al-Adhami
NJNigel Jamieson
Nigel Jamieson
JVJuan Valle
Juan Valle
GRGanesh Radhakrishna
Ganesh Radhakrishna
RAR. Albazaz
R. Albazaz
Pancreatic ductal adenocarcinoma continues to have a poor prognosis, although recent advances in neoadjuvant treatments (NATs) have provided some hope. Imaging assessment of suspected tumours can be challenging and requires a specific approach, with pancreas protocol CT being the primary imaging modality for staging with other modalities used as problem-solving tools to facilitate appropriate management. Imaging assessment post NAT can be particularly difficult due to a current lack of robust radiological criteria to predict response and differentiate treatment induced fibrosis/inflammation from residual tumour. This review aims to provide an update of pancreatic ductal adenocarcinoma with particular focus on three points: tumour staging pre- and post-NAT including vascular assessment, structured reporting with introduction of the PAncreatic Cancer reporting Template—UK (PACT-UK) radiology template, and the potential future role of artificial intelligence in the diagnosis and staging of pancreatic cancer.

1 November 2020 in Clinical Radiology
Verified
Journal Article
Closed access
RAR. Allard
R. Allard
CSC. Smith
C. Smith
JZJ. Zhong
J. Zhong
MSM. Sheridan
M. Sheridan
AGA. Guthrie
A. Guthrie
RAR. Albazaz
R. Albazaz

22 July 2021 in British Journal of Radiology
Verified
Journal Article
Closed access
JZJim Zhong
Jim Zhong
RARachel Allard
Rachel Allard
DHDominic Hewitson
Dominic Hewitson
MWMichael Weston
Michael Weston
OHOliver Hulson
Oliver Hulson
RAR. Albazaz
R. Albazaz
Objectives: To determine biopsy device failures, causative factors, complications and sample quality of the 16G end-cut Biopince™ and side-notch Bard™ needles. Methods: All ultrasound-guided non-targeted liver biopsies between 01/01/2016 and 31/12/2018 were included. Operator, device, number of failures, complications and repeat biopsies were recorded. Histopathology samples were reviewed for all cases of needle failure and a group with no failures, and graded “yes/no” for the presence of steatosis, inflammation and fibrosis. The pathology slides from these cases were reviewed to assess biopsy sample quality (length and portal tract number). The failure and no-failure groups were compared in terms of device type/histology, and sample quality was compared between the needle types. Results: 1004 patients were included. 93.8% (n = 942) required one needle pass to obtain a sample and 6.2% (n = 62) required >1 pass due to needle failure. Total of 76 needle failures, more with end-cut than side-notch needles (8.7% vs 2.9%) (p < 0.001). No needle failures resulted in complication. The presence of liver fibrosis was associated with fewer needle failures (p = 0.036). The major complication rate was 0.4% (4/1044). A biopsy with >10 portal tracts was obtained in 90.2% of specimens > 20 mm long, compared with 66% of 16–20 mm biopsies and 21% of 10 portal tracts was achieved in 10/26 (38.5%) of side-notch biopsies and 64/90 (71.1%) of end-cut biopsies (p = 0.004). Conclusion: Ultrasound-guided liver biopsy is safe and sample quality is consistently good when a core >20 mm long is obtained. The end-cut biopsy device generated reliably good quality biopsy samples; however, the needle failure rate was significantly higher than the side-cut needle. Advances in knowledge: Ultrasound-guided liver biopsy specimen quality is consistently good when a core >20 mm long is obtained which can be achieved with a single pass using the 16G BiopinceTM end-cut needle, although the needle failure rate is significantly higher than the 16G Max-Core™ Bard™ side-notch needle.

19 October 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
RGRachel Gravell
Rachel Gravell
RFRussell Frood
Russell Frood
ALAnna Littlejohns
Anna Littlejohns
NCNathalie Casanova
Nathalie Casanova
RGRebecca Goody
Rebecca Goody
ASAndrew Scarsbrook
Andrew Scarsbrook
Background: The study purpose was to develop a machine learning (ML)-based predictive model for event-free survival (EFS) in patients with hepatocellular carcinoma (HCC) undergoing stereotactic ablative radiotherapy (SABR). Methods: Patients receiving SABR for HCC at a single institution, between 2017 and 2020, were included in the study. They were split into training and test (85%:15%) cohorts. Events of interest were HCC recurrence or death. Three ML models were trained, the features were selected, and the hyperparameters were tuned. The performance was measured using Harrell’s C index with the best-performing model being tested on the unseen cohort. Results: Overall, 41 patients were included (training = 34, test = 7) and 64 lesions were analysed (training = 50, test = 14), resulting in 30 events (60% rate) in the training set (death = 6, recurrence = 24) and 8 events (57% rate) in the test set (death = 5, recurrence = 3). A Cox regression model, using age at treatment, albumin, and intra-lesional fat identified through MRI as variables, had the best performance with a mean training score of 0.78 (standard deviation (SD) 0.02), a mean validation of 0.78 (SD 0.18), and a test score of 0.94. Conclusions: Predicting the outcomes in patients with HCC, following SABR, using a novel model is feasible and warrants further evaluation.